Background: Patients with remitted psychosis face a dilemma between the wish to discontinue antipsychotics and the risk of relapse. We test if an operationalized guided-dose-reduction algorithm can help reach a lower effective dose without increased risks of relapse.
Methods: A 2-year open-label randomized prospective comparative cohort trial from Aug 2017 to Sep 2022. Patients with a history of schizophrenia-related psychotic disorders under stable medications and symptoms were eligible, randomized 2:1 into guided dose reduction group (GDR) maintenance treatment group (MT1), together with a group of naturalistic maintenance controls (MT2). We observed if the relapse rates would be different between 3 groups, to what extent the dose could be reduced, and if GDR patients could have improved functioning and quality of life.
Results: A total of 96 patients, comprised 51, 24, and 21 patients in GDR, MT1, and MT2 groups, respectively. During follow-up, 14 patients (14.6%) relapsed, including 6, 4, and 4 from GDR, MT1, and MT2, statistically no difference between groups. In total, 74.5% of GDR patients could stay well under a lower dose, including 18 patients (35.3%) conducting 4 consecutive dose-tapering and staying well after reducing 58.5% of their baseline dose. The GDR group exhibited improved clinical outcomes and endorsed better quality of life.
Conclusions: GDR is a feasible approach as the majority of patients had a chance to taper antipsychotics to certain extents. Still, 25.5% of GDR patients could not successfully decrease any dose, including 11.8% experienced relapse, a risk comparable to their maintenance counterparts.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10719630 | PMC |
http://dx.doi.org/10.1017/S0033291723000429 | DOI Listing |
Fortschr Neurol Psychiatr
December 2024
Medizinische Fakultät der Universität Leipzig, Forschungsstelle für die Geschichte der Psychiatrie, Klinik und Poliklinik für Psychiatrie und Psychotherapie, Leipzig, Germany.
Objective: The aim of this study was to provide insights into the addiction therapy concepts applied at the clinics of Hugo von Keyserlingk in Schwerin and Hubertus Windischmann in Brandenburg and to enable an understanding of the specific problems in this subsector of psychiatric care in the GDR.
Methods: Works published primarily in the GDR were identified, analyzed and contextualized, with expert interviews with von Keyserlingk and Windischmann complementing the findings.
Results: Initially limited approaches to alcoholism treatment after the Second World War gradually developed into more complex and diverse structures.
Circ Arrhythm Electrophysiol
December 2024
Heart Rhythm Management Centre, Postgraduate Program in Cardiac Electrophysiology and Pacing, European Reference Networks Guard-Heart (L.P., D.G.D.R., P.V., A. Sorgente, A.D.M., G.V., M.C.F., G.T., I.E., P.-A.C., I.O., G.B., A.A., E.S., G.P., J.S., A.G., P.B., G.B.C., A. Sarkozy, C.d.A.), Universitair Ziekenhuis Brussel-Vrije Universiteit Brussel, Belgium.
Cardiol J
November 2024
Department of Cardiology, Institute of Heart Diseases, University Hospital, Wroclaw, Poland.
Background: The aim of the study was to analyze the potential relationship between the diuretic response, the clinical profile and the concentrations of selected biochemical markers and to identify a group of patients who will benefit from a new form of therapy combining standard diuretic therapy with the use of a RenalGuard® system.
Methods: This is a retrospective study of 19 patients (mean age 67 ± 10 years, 95% men) hospitalized due to acute decompensated heart failure (ADHF, NYHA class III-IV, BP 125 ± 14/73 ± 16 mmHg, eGFR 58 ± 24) with persistent overhydration despite standard therapy. A targeted comparative analysis of selected clinical and biochemical parameters was performed to determine the parameters associated with a better diuretic response [good diuretic responders (GDR) group].
J Affect Disord
February 2025
Institut de Psychiatrie (CNRS GDR 3557), Paris 75000, France; Établissement public de santé mentale Barthélémy Durand, Etampes 91150, France; Université Paris-Saclay, Centre Hospitalier Kremlin-Bicêtre, 94270, France; Laboratoire de recherche PSYCOMADD, Centre Hospitalier Paul Brousse, Villejuif, 94800, France; Centre de Recherche en Epidémiologie et Santé des Populations, UMR 1018, Université Paris-Saclay, UVSQ, France.
Background: Patients with bipolar disorders (BD) have significant impairments in Facial Expression Recognition (FER), an essential social skill for effective social interactions. While the Facial Emotions Recognition Test, 54 photographs by Gaudelus (TREF-54g) has been used in patients with schizophrenia, no study has evaluated FER using this test in BD patients. The TREF-54g meets the International Society for Bipolar Disorders (ISBD) criteria for assessing FER.
View Article and Find Full Text PDFCirc Heart Fail
December 2024
School of Medical Sciences, Faculty of Medicine and Health, University of Sydney, NSW, Australia (A.L., B.F., Y.C.K., C.M., B.H., D.H., C.G.d.R., M. Larance, J.F.O., S.L.).
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!